机译:在接受化疗的HBsAg阳性癌症患者中胞藤虫毒性富马酸富马酸核和Entecavir抗病毒预防肾事件风险
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Cancer CenterTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
cancer; chemotherapy; entecavir; hepatitis B virus; tenofovir;
机译:在接受化疗的HBsAg阳性癌症患者中胞藤虫毒性富马酸富马酸核和Entecavir抗病毒预防肾事件风险
机译:癌症患者肾功能损害风险在化疗期间对HBV预防治疗的癌症患者
机译:乙型肝炎表面抗原在患有癌症化疗患者患者中埃西哥韦或替诺福韦预防后乙型肝炎病毒复发的作用
机译:Cox-2和VEGF在接受新辅助化疗的乳腺癌患者中的预后意义
机译:一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局,利用和支出的影响。
机译:在单独接受Peg-IFNα-2b治疗12周后反应较差的HBeAg阳性CHB患者中向Peg-IFNα-2b中添加富马酸替诺福韦酯富马酸的疗效优于恩替卡韦
机译:社论:替诺福韦富有富马特对慢性乙型肝炎患者患者的富马酸核毒素和肾脏损伤 - 仍然是一个开放的问题